Inge J. Stijleman

TL;DR: D diagnosis by intrinsic subtype adds significant prognostic and predictive information to standard parameters for patients with breast cancer.

TL;DR: The PAM50 gene expression test for intrinsic biological subtype can be applied to large series of formalin-fixed, paraffin-embedded breast cancers, and gives more prognostic information than clinical factors and IHC using standard cut points.

TL;DR: The HER2-E showed the greatest benefit from CEF versus CMF, with absolute 5-year RFS and OS differences exceeding 20%, whereas the chemotherapy-sensitive basal-like tumors showed no added benefit for CEF overCMF, suggesting that nonanthracycline regimens may be adequate in this subtype although further investigation is required.

TL;DR: It is indicated that over 50% of breast cancers treated in the community have luminal A subtype, and Gene expression–based classification shifted some tumors categorized as low risk by surrogate clinicopathologic criteria to higher-risk subtypes.

TL;DR: The PAM50 proliferation score identifies a subset of patients with a low proliferation status that may derive a larger benefit from weekly paclitaxel and results were obtained in the CALGB data set, although the interaction test did not reach statistical significance.